Regulation of DARPP-32 phosphorylation by three distinct dopamine D 1-like receptor signaling pathways in the neostriatum

Journal of Neurochemistry

Volumn 107, Issue 4, 2008, Pages 1014-1026

  Kuroiwa, Mahomi ^a   Bateup, Helen S ^c   Shuto, Takahide ^a   Higashi, Hideho ^a   Tanaka, Masatoshi ^a   Nishi, Akinori ^a,b,c  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Adenosine A2a receptor; DARPP 32; Phospholipase C; PKA; Striatum

Indexed keywords

1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ADENOSINE A2 RECEPTOR ANTAGONIST; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOSPORIN A; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR STIMULATING AGENT; PHOSPHOPROTEIN DARPP 32; RACLOPRIDE; SKF 83822; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; MALE; MOUSE; NEOSTRIATUM; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; CYCLOSPORINE; DOPAMINE AGENTS; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; ESTRENES; MALE; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NEOSTRIATUM; PHOSPHORYLATION; PYRROLIDINONES; RECEPTORS, DOPAMINE D1; SIGNAL TRANSDUCTION; THREONINE; TIME FACTORS;

MUS;

EID: 54349112923     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2008.05702.x     Document Type: Article

References (56)

1. Adachi K., Ikeda H., Hasegawa M., Nakamura S., Waddington J. L. Koshikawa N. (1999) SK&F 83959 and non-cyclase-coupled dopamine D1-like receptors in jaw movements via dopamine D1-like/D2-like receptor synergism. Eur. J. Pharmacol. 367, 143 149.
2. 1 antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia. Psychopharmacology (Berl) 146, 328 334.
3. 1 receptor antagonist in primate cells and interacts with other receptors. Eur. J. Pharmacol. 364, 33 41.
4. 1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. Eur. J. Pharmacol. 213, 259 267.
5. Bateup H. S., Svenningsson P., Kuroiwa M., Gong S., Nishi A., Heintz N. Greengard P. (2008) Cell type-specific regulation of DARPP-32 phosphorylation by psychostimulant and antipsychotic drugs. Nat. Neurosci. 11, 932 939.
6. Bibb J. A., Snyder G. L., Nishi A. et al. (1999) Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature 402, 669 671.
7. Cooper D. M. (2003) Molecular and cellular requirements for the regulation of adenylate cyclases by calcium. Biochem. Soc. Trans. 31, 912 915.
8. 1 dopamine receptor regulated intracellular calcium transients. Neurosignals 16, 112 123.
9. Deveney A. M. Waddington J. L. (1995) Pharmacological characterization of behavioural responses to SK&F 83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase. Br. J. Pharmacol. 116, 2120 2126.
10. Felder C. C., Jose P. A. Axelrod J. (1989) The dopamine-1 agonist, SKF 82526, stimulates phospholipase-C activity independent of adenylate cyclase. J. Pharmacol. Exp. Ther. 248, 171 175.
11. 1A knockout mice. Mol. Pharmacol. 51, 6 11.
12. Fujita S., Lee J., Kiguchi M., Uchida T., Cools A. R., Waddington J. L. Koshikawa N. (2006) Topographical resolution of jaw movements mediated by cyclase- vs. non-cyclase-coupled dopamine D1-like receptors: studies with SK&F 83822. Eur. J. Pharmacol. 538, 94 100.
13. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science 250, 1429 1432.
14. Glatt C. E. Snyder S. H. (1993) Cloning and expression of an adenylyl cyclase localized to the corpus striatum. Nature 361, 536 538.
15. 1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacology (Berl) 117, 287 297.
16. Gnanalingham K. K., Hunter A. J., Jenner P. Marsden C. D. (1995b) Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat - relationship to circling behaviour. Biochem. Pharmacol. 49, 1185 1193.
17. 1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacology (Berl) 117, 275 286.
18. Hamada M., Hendrick J. P., Ryan G. R., Kuroiwa M., Higashi H., Tanaka M., Nairn A. C., Greengard P. Nishi A. (2005) Nicotine regulates DARPP-32 (dopamine- and cAMP-regulated phosphoprotein of 32 kDa) phosphorylation at multiple sites in neostriatal neurons. J. Pharmacol. Exp. Ther. 315, 872 878.
19. Hemmings H. C. Jr. Greengard P. (1986) DARPP-32, a dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein: regional, tissue, and phylogenetic distribution. J. Neurosci. 6, 1469 1481.
20. β1-IP3-calcineurin-signaling cascade. J. Neurosci. 20, 8987 8995.
21. 2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. J. Neurosci. 15, 5222 5237.
22. olf levels are regulated by receptor usage and control dopamine and adenosine action in the striatum. J. Neurosci. 21, 4390 4399.
23. 1 dopamine receptors couple to multiple Gα proteins in different brain regions. J. Neurochem. 78, 981 990.
24. 1 dopamine receptors in rat brain. J. Neurochem. 85, 378 386.
25. Liu F., Ma X. H., Ule J., Bibb J. A., Nishi A., DeMaggio A. J., Yan Z., Nairn A. C. Greengard P. (2001) Regulation of cyclin-dependent kinase 5 and casein kinase 1 by metabotropic glutamate receptors. Proc. Natl Acad. Sci. USA 98, 11062 11068.
26. 2+ mobilization in Xenopus oocytes. Proc. Natl Acad. Sci. USA 87, 2196 2200.
27. q in rat striatum and cortex: a scintillation proximity assay (SPA)/antibody- capture characterization of benzazepine agonists. Neuropharmacology 52, 1003 1014.
28. 2a receptor modulation of electrically evoked endogenous GABA release from slices of rat globus pallidus. J. Neurochem. 60, 2334 2337.
29. 1 dopamine receptor in hippocampal neurons. J. Neurochem. 98, 1316 1323.
30. Missale C., Nash S. R., Robinson S. W., Jaber M. Caron M. G. (1998) Dopamine receptors: from structure to function. Physiol. Rev. 78, 189 225.
31. Nishi A., Snyder G. L. Greengard P. (1997) Bidirectional regulation of DARPP-32 phosphorylation by dopamine. J. Neurosci. 17, 8147 8155.
32. Nishi A., Bibb J. A., Snyder G. L., Higashi H., Nairn A. C. Greengard P. (2000) Amplification of dopaminergic signaling by a positive feedback loop. Proc. Natl Acad. Sci. USA 97, 12840 12845.
33. Nishi A., Bibb J. A., Matsuyama S., Hamada M., Higashi H., Nairn A. C. Greengard P. (2002) Regulation of DARPP-32 dephosphorylation at PKA- and Cdk5-sites by NMDA and AMPA receptors: distinct roles of calcineurin and protein phosphatase-2A. J. Neurochem. 81, 832 841.
34. O'Sullivan G. J., Roth B. L., Kinsella A. Waddington J. L. (2004) SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography. Eur. J. Pharmacol. 486, 273 280.
35. 5 receptor-dependent induction of seizures in relation to DARPP-32, ERK1/2 and GluR1-AMPA signalling. Neuropharmacology 54, 1051 1061.
36. 35S]GTP gamma S binding and phosphoinositide hydrolysis in rat and monkey brain. Neuropharmacology 40, 826 837.
37. Pendleton R. G., Parvez F., Sayed M. Hillman R. (2002) Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. J. Pharmacol. Exp. Ther. 300, 91 96.
38. q/11-coupled dopamine receptors: an uncharted role for dopamine. Trends Pharmacol. Sci. 28, 551 555.
39. q/11 in the striatum. Proc. Natl Acad. Sci. USA 104, 654 659.
40. 1 receptor agonists. Mol. Pharmacol. 68, 1039 1048.
41. Seeman P. Van Tol H. H. (1994) Dopamine receptor pharmacology. Trends Pharmacol. Sci. 15, 264 270.
42. Snyder G. L., Girault J.-A., Chen J. Y. C., Czernik A. J., Kebabian J. W., Nathanson J. A. Greengard P. (1992) Phosphorylation of DARPP-32 and protein phosphatase inhibitor-1 in rat choroid plexus: Regulation by factors other than dopamine. J. Neurosci. 12, 3071 3083.
43. Snyder G. L., Fisone G. Greengard P. (1994) Phosphorylation of DARPP-32 is regulated by GABA in rat striatum and substantia nigra. J. Neurochem. 63, 1766 1771.
44. 1 receptors stimulates cyclicAMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience 84, 223 228.
45. 2A receptors. Prog. Neurobiol. 59, 355 396.
46. Svenningsson P., Nishi A., Fisone G., Girault J. A., Nairn A. C. Greengard P. (2004) DARPP-32: an integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 44, 269 296.
47. Taverna S., Ilijic E. Surmeier D. J. (2008) Recurrent collateral connections of striatal medium spiny neurons are disrupted in models of Parkinson's disease. J. Neurosci. 28, 5504 5512.
48. 1A receptor 'knockout' mice. Neuropharmacology 42, 644 652.
49. 1 receptor enhances inositol phosphates formation in rat brain. J. Pharmacol. Exp. Ther. 253, 987 992.
50. 1-like dopamine receptor that couples to activation of phosphoinositide metabolism in brain. J. Neurochem. 62, 2045 2048.
51. Undie A. S., Berki A. C. Beardsley K. (2000) Dopaminergic behaviors and signal transduction mediated through adenylate cyclase and phospholipase C pathways. Neuropharmacology 39, 75 87.
52. 1 receptor agonist, SKF 81297, stimulates motor behaviour of MPTP-lesioned monkeys. Eur. J. Pharmacol. 235, 143 147.
53. 1-like dopamine sites in rat striatum: possible role in dopamine-mediated inositol phosphate formation. Mol. Pharmacol. 48, 988 994.
54. 1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 79, 729 742.
55. Yabuuchi K., Kuroiwa M., Shuto T., Sotogaku N., Snyder G. L., Higashi H., Tanaka M., Greengard P. Nishi A. (2006) Role of adenosine A(1) receptors in the modulation of dopamine D(1) and adenosine A(2a) receptor signaling in the neostriatum. Neuroscience 141, 19 25.
56. 1 dopamine receptor in the pharmacology of SKF83959. Pharmacol. Biochem. Behav. 80, 597 601.